Autopsy report · NCT02336425
Efficacy and Safety of QGE031 Compared With Placebo in Patients Aged 18-75 Years With Asthma
Cause of deathOther
“This study was terminated due to the efficacy results from an interim analysis (at the end of treatment epoch) of the Phase II study CQGE031B2201 (NCT01716754).”
Life of this trial
- Registered 8 months before it started.
- Ran for about 6 months before it stopped.
- 10 participants enrolled.
- Results were posted on the registry 1 year 1 month after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Novartis Pharmaceuticals
- Sponsor type
- Industry
- Conditions
- Asthma
- Interventions
- QGE031; Placebo
- Participants
- 10
- Sites
- 37
- Countries
- Belgium, Canada, France, Germany, Hungary, Italy, Japan, Netherlands, Slovakia, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.